Author/Authors :
Warnke، نويسنده , , Clemens and Leussink، نويسنده , , Verena I. and Goebels، نويسنده , , Norbert and Aktas، نويسنده , , Orhan and Boyko، نويسنده , , Alexey and Kieseier، نويسنده , , Bernd C. and Hartung، نويسنده , , Hans-Peter، نويسنده ,
Abstract :
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug.
Keywords :
Cladribine , immunosuppressant , Multiple sclerosis , oral drugs
